US HB3678 | 2015-2016 | 114th Congress

Status

Spectrum: Moderate Partisan Bill (Republican 9-2)
Status: Introduced on October 1 2015 - 25% progression, died in committee
Action: 2015-10-02 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Preserving Access to Orphan Drugs Act of 2015 This bill amends the Patient Protection and Affordable Care Act to expand the definition of orphan drug for purposes of the annual fee paid by brand name prescription drug manufacturers and importers to include medications for rare conditions that were, prior to 2011, approved or in clinical trials. (Drug manufacturers and importers pay an annual fee based on their sales of brand name prescription drugs, excluding sales of orphan drugs.) Currently, only medications for rare conditions for which a tax credit for clinical trials was allowed are considered orphan drugs. This Act applies to fees paid after 2014.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Preserving Access to Orphan Drugs Act of 2015

Sponsors


History

DateChamberAction
2015-10-02HouseReferred to the Subcommittee on Health.
2015-10-01HouseReferred to the Subcommittee on Health.
2015-10-01HouseReferred to House Energy and Commerce
2015-10-01HouseReferred to House Ways and Means
2015-10-01HouseReferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2015-10-01HouseIntroduced in House

Subjects


US Congress State Sources


Bill Comments

feedback